Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06738368
Title	Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	University of Washington
Indications	T-cell acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia
Therapies	Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + JZP-458 + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + JZP-458 + Pegfilgrastim + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + JZP-458 + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + JZP-458 + Pegfilgrastim + Prednisone + Vincristine Sulfate
Age Groups:	adult \| senior
Covered Countries	USA